FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ESTERO, FL / ACCESS Newswire / January 7, 2026 / Aspire Biopharma ...
Investing.com -- Aspire Biopharma Holdings Inc (NASDAQ:ASBP) stock surged 60.6% in premarket trading Wednesday after the company announced a successful pre-IND meeting with the FDA for its emergency ...
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disordersAlprazolam, sold under the brand name Xanax among others, wa ...
Stocktwits on MSN
ASBP stock soars 32% after favorable feedback from FDA for its aspirin – retail expects licensing negotiations soon
Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial. ・The firm said OTASA demonstrated faster and higher absorption of ...
President Donald Trump said he takes more aspirin daily than his doctors recommend, continuing the routine for years and referring to it as a “superstition.” “They say aspirin is good for thinning out ...
President Donald Trump's disclosure that he takes a large daily dose of aspirin to prevent the onset of cardiac disease, despite his doctor's recommendation he take less, has brought new public ...
Despite his doctors’ recommendations, President Trump takes a high dose. By Nina Agrawal President Trump takes a high daily dose of aspirin, and has done so for over two decades, rejecting medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback